SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Drugs that provide the splice of life: Motor neurons relay signals from the nervous system to muscle fibers. In patients with spinal muscular atrophy, a protein required for the survival of these neurons is deficient or missing altogether, so the neurons gradually die and the patients' muscles waste away. The disease is currently untreatable. Naryshkin et al. discovered small-molecule drugs that cause cells to produce the missing protein by altering how a specific mRNA is put together, or “spliced” (see the Perspective by Vigevani and Valcárcel). When the researchers used the drugs to treat diseased mice, the mice showed marked improvement in muscle mass, motor function, and survival. Science , this issue p. 688 ; see also p. 624
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These screens, which are typically conducted in genetically engineered cell lines that harbour the target of interest, led to the discovery of the splice modulators risdiplam106 and branaplam107 for the treatment of spinal muscular atrophy”
From Human disease models in drug development (2023) · cites this paper as [106]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
GMAP: A genomic mapping and alignment program for mRNA and EST sequences
Wu, T. D., & Watanabe, C. K. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti310 · Cited by 2,354
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961
Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 741
Cited by
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Malard, F., Wolter, A. C., Marquevielle, J., Morvan, E., Ecoutin, A., Rüdisser, S. H., Allain, F. H. T., & Campagne, S. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae201 · Cited by 1,273
“In recent decades, synthetic tools that enable the modulation of 5 (cid:2) -splice site selection and the correction of alternative splicing have emerged and have begun to offer therapeutics for inherited diseases ( 12–16 ).”
BackgroundScotti, M. M., & Swanson, M. S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.3 · Cited by 1,163
Huntington's disease: a clinical review
McColgan, P., & Tabrizi, S. J. (2018) · European Journal of Neurology · doi:10.1111/ene.13413 · Cited by 1,089
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Targeting RNA structures with small molecules
Childs-Disney, J. L., Yang, X., Gibaut, Q. M. R., Tong, Y., Batey, R. T., & Disney, M. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00521-4 · Cited by 587
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Ratni, H., Ebeling, M., Baird, J., Bendels, S., Bylund, J., Chen, K. S., Denk, N., Feng, Z., Green, L., Guerard, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00741 · Cited by 537
Self-citationSMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA mice
Palacino, J., Swalley, S. E., Song, C., Cheung, A. K., Shu, L., Zhang, X., Van Hoosear, M., Shin, Y., Chin, D. N., Keller, C. G., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1837 · Cited by 432
Self-citationRNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
“Indeed, a pyrimi-din-4-one analog, SMN-C3, was first identified as an effective SMN2 splicing modifier through chemical screening and optimization (Naryshkin et al., 2014).”
BackgroundPhenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
Bennett, C. F., Krainer, A. R., & Cleveland, D. W. (2019) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050501 · Cited by 353
“Although there has been some encouraging progress in the identification of small-molecule drugs that modulate RNA function (Naryshkin et al. 2014, Palacino et al. 2015), antisense oligonucleotides (ASOs) offer a more direct approach.”
BackgroundHuntingtin Lowering Strategies for Disease Modification in Huntington’s Disease
Tabrizi, S. J., Ghosh, R., & Leavitt, B. R. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.039 · Cited by 337
Human disease models in drug development
Loewa, A., Feng, J. J., & Hedtrich, S. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00063-3 · Cited by 331
The Emerging Role of RNA as a Therapeutic Target for Small Molecules
Connelly, C. M., Moon, M. H., & Schneekloth, J. S. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.05.021 · Cited by 316
“Another prominent example of phenotypic screening comes from the study of spinal muscular atrophy (SMA), a life-threatening motor neuron disease that is caused by the deficiency of the survival of motor neuron (SMN) protein (Palacino et al., 2015).”
BackgroundInfluentialSplicing-factor alterations in cancers
Anczuków, O., & Krainer, A. R. (2016) · RNA · doi:10.1261/rna.057919.116 · Cited by 302
“For example, several groups identified compounds that enhance SMN2 exon 7 splicing to promote the production of a full-length SMN protein (Hastings et al. 2009; Naryshkin et al. 2014; Palacino et al. 2015), an approach with therapeutic potential for spinal muscular atrophy.”
Therapies targeting DNA and RNA in Huntington's disease
Wild, E. J., & Tabrizi, S. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30280-6 · Cited by 298
“In patient fibroblasts, these increased SMN concentration in a dose-dependent manner, and improved outcomes in an SMA mouse model – albeit through uncertain mechanisms.(64) A phase 1b/2a clinical trial in SMA of the lead compound, RG7800, was terminated after ocular complications emerged in ongoing animal studies,(65)…”
Machine Learning in Genomic Medicine: A Review of Computational Problems and Data Sets
Leung, M. K. K., Delong, A., Alipanahi, B., & Frey, B. J. (2016) · Proceedings of the IEEE · doi:10.1109/jproc.2015.2494198 · Cited by 275
“Researchers are evaluating therapies that restore function of exon 7 in SMN2 [14], [15].”
BackgroundLancet Commission: Stem cells and regenerative medicine
Cossu, G., Birchall, M., Brown, T., De Coppi, P., Culme-Seymour, E., Gibbon, S., Hitchcock, J., Mason, C., Montgomery, J., Morris, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31366-1 · Cited by 272
Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions
Nussbacher, J. K., Tabet, R., Yeo, G. W., & Lagier-Tourenne, C. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.014 · Cited by 272
“…using small molecules that successfully restored full-length SMN2 protein in two mouse models through recruitment of the U1 snRNP (Figure 2Aii) (Naryshkin et al., 2014; Pinard et al., 2017; Sivaramakrishnan et al., 2017), which normally has a weak interaction with the 50 splice site of exon 7…”
BackgroundWirth, B., Karakaya, M., Kye, M. J., & Mendoza-Ferreira, N. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-102319-103602 · Cited by 255
“Oral administration to severe SMA mice extended their life spans, led to increased SMN levels, protected theNMJ, and improvedmotor function (128, 140, 141).”
BackgroundMethodEmerging therapies and challenges in spinal muscular atrophy
Farrar, M. A., Park, S. B., Vucic, S., Carey, K. A., Turner, B. J., Gillingwater, T. H., Swoboda, K. J., & Kiernan, M. C. (2017) · Annals of Neurology · doi:10.1002/ana.24864 · Cited by 247
Advances in therapy for spinal muscular atrophy: promises and challenges
Groen, E. J. N., Talbot, K., & Gillingwater, T. H. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.4 · Cited by 235
Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers
Sivaramakrishnan, M., McCarthy, K. D., Campagne, S., Huber, S., Meier, S., Augustin, A., Heckel, T., Meistermann, H., Hug, M. N., Birrer, P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01559-4 · Cited by 226
“In Naryshkin et al. 2014 16 , we introduced a compound class of orally bioavailable splicing modi fi ers (SMN-C class) that promote SMN2 exon 7 inclusion, and hypothesized that they are involved in speci fi c protein – RNA and/or RNA – RNA interactions.”
Self-citationSelective Small-Molecule Targeting of a Triple Helix Encoded by the Long Noncoding RNA, MALAT1
Abulwerdi, F. A., Xu, W., Ageeli, A. A., Yonkunas, M. J., Arun, G., Nam, H., Schneekloth, J. S., Dayie, T. K., Spector, D., Baird, N., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b00807 · Cited by 214
Defective control of pre–messenger RNA splicing in human disease
Chabot, B., & Shkreta, L. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201510032 · Cited by 213
“, 2015) or small molecules that stimulate exon 7 inclusion with apparent high specificity (Naryshkin et al., 2014; Palacino et al., 2015).”
BackgroundDisney, M. D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13419 · Cited by 203
Omole, A. E., & Fakoya, A. O. J. (2018) · PeerJ · doi:10.7717/peerj.4370 · Cited by 204
Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit
Van Alstyne, M., Tattoli, I., Delestrée, N., Recinos, Y., Workman, E., Shihabuddin, L. S., Zhang, C., Mentis, G. Z., & Pellizzoni, L. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00827-3 · Cited by 188
Dangouloff, T., & Servais, L. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s172291 · Cited by 196
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment
Ramos, D. M., d’Ydewalle, C., Gabbeta, V., Dakka, A., Klein, S. K., Norris, D. A., Matson, J., Taylor, S. J., Zaworski, P. G., Prior, T. W., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124120 · Cited by 190
Self-citationGene-based therapies for neurodegenerative diseases
Sun, J., & Roy, S. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00778-1 · Cited by 187
Disease Mechanisms and Therapeutic Approaches in Spinal Muscular Atrophy
Tisdale, S., & Pellizzoni, L. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0417-15.2015 · Cited by 187
“Cell-based high-throughput screens were performed to identify small molecules that increase SMN expression and their therapeutic potential was investigated in SMA mice (Jarecki et al., 2005; Cherry et al., 2013; Naryshkin et al., 2014).”
BackgroundWhere Do Recent Small Molecule Clinical Development Candidates Come From?
Brown, D. G., & Boström, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00675 · Cited by 176
Poirier, A., Weetall, M., Heinig, K., Bucheli, F., Schoenlein, K., Alsenz, J., Bassett, S., Ullah, M., Senn, C., Ratni, H., et al. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.447 · Cited by 172
Self-citationRegulation of Neuronal Differentiation, Function, and Plasticity by Alternative Splicing
Furlanis, E., & Scheiffele, P. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062826 · Cited by 174
“…in rodent models of Spinal Muscular Atrophy (SMA), a neurodegenerative disorder, antisense oligonucleotides (Hua et al., 2011) and small molecules (Naryshkin et al., 2014) that modify splicing of the endogenous SMN2 (survival motor neuron 2) gene have shown to recover SMN2 splicing activity and…”
BackgroundNusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Gidaro, T., & Servais, L. (2019) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14027 · Cited by 144
Chaytow, H., Faller, K. M. E., Huang, Y.-T., & Gillingwater, T. H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100346 · Cited by 165
“Risdiplam belongs to the SMN-C class of splice modulators: it increased full-length SMN protein in both severe and mild mouse models of SMA, with an increase in survival and improvement of motor phenotypes.(41) Oral dosing of risdiplam at 3 mg/kg/day for 7 days in non-human primates showed good biodistribution in rele…”
BackgroundStructural basis of a small molecule targeting RNA for a specific splicing correction
Campagne, S., Boigner, S., Rüdisser, S., Moursy, A., Gillioz, L., Knörlein, A., Hall, J., Ratni, H., Cléry, A., & Allain, F. H.-T. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0384-5 · Cited by 162
Self-citationTherapeutic Advances for Huntington’s Disease
Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J. (2020) · Brain Sciences · doi:10.3390/brainsci10010043 · Cited by 164
Nusinersen for the treatment of spinal muscular atrophy
Chiriboga, C. A. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1364159 · Cited by 162
Patient-derived induced pluripotent stem cells in cancer research and precision oncology
Papapetrou, E. P. (2016) · Nature Medicine · doi:10.1038/nm.4238 · Cited by 160
Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment
Nishio, H., Niba, E. T. E., Saito, T., Okamoto, K., Takeshima, Y., & Awano, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511939 · Cited by 201
“After the discovery of compounds that correct SMN2 splicing, researchers performed high-throughput screening of compounds with similar functions, resulting in the discovery of SMN-C3 [116].”
BackgroundDaguenet, É., Dujardin, G., & Valcárcel, J. (2015) · EMBO Reports · doi:10.15252/embr.201541116 · Cited by 175
The era of cryptic exons: implications for ALS-FTD
Mehta, P. R., Brown, A.-L., Ward, M. E., & Fratta, P. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00608-5 · Cited by 146
Teng, T., Tsai, J., Puyang, X., Seiler, M., Peng, S., Prajapati, S., Aird, D. R., Buonamici, S., Caleb, B. L., Chan, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15522 · Cited by 153
Ratni, H., Scalco, R., & Stephan, A. H. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00659 · Cited by 153
Self-citationComplex Tissue and Disease Modeling using hiPSCs
Passier, R., Orlova, V., & Mummery, C. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.02.011 · Cited by 142
“These include amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and Alzheimer’s disease (AD) (Bright et al., 2015; McNeish et al., 2015; Naryshkin et al., 2014; Wainger et al., 2014).”
BackgroundStem Cells, Genome Editing, and the Path to Translational Medicine
Soldner, F., & Jaenisch, R. (2018) · Cell · doi:10.1016/j.cell.2018.09.010 · Cited by 142
“These includes a novel class of splicing modifying compounds to treat spinal muscular atrophy (Naryshkin et al., 2014) (https://clinicaltrials.gov; NCT02913482), a humanized antibody targeting secreted eTau to treat tauopathies (Bright et al., 2015), including progressive supranuclear palsy…”
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
Bakowski, M. A., Beutler, N., Wolff, K. C., Kirkpatrick, M. G., Chen, E., Nguyen, T.-T. H., Riva, L., Shaabani, N., Parren, M., Ricketts, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23328-0 · Cited by 138
Base editing rescue of spinal muscular atrophy in cells and in mice
Arbab, M., Matuszek, Z., Kray, K. M., Du, A., Newby, G. A., Blatnik, A. J., Raguram, A., Richter, M. F., Zhao, K. T., Levy, J. M., et al. (2023) · Science · doi:10.1126/science.adg6518 · Cited by 139
“We therefore sought to extend the effective therapeutic window for gene editing by transient early administration of an existing approved SMA drug to attenuate disease progression, as has previously been applied to study milder forms of SMA in mice (72, 96, 97).”
BackgroundSpinal muscular atrophy: A changing phenotype beyond the clinical trials
Tizzano, E. F., & Finkel, R. S. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.05.011 · Cited by 151
“From a therapeutic perspective, a precise focus in drug development has targeted the SMN genes in two ways: (1) transfer of a correct version of the SMN1 gene using a scAAV9 vector [21], and (2) the modulation of SMN2 pre-mRNA splicing by antisense oligonucleotides (ASO) [22] or by small molecule drugs to increase the…”
BackgroundSpinal muscular atrophy—recent therapeutic advances for an old challenge
Faravelli, I., Nizzardo, M., Comi, G. P., & Corti, S. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.77 · Cited by 138
d’Ydewalle, C., Ramos, D. M., Pyles, N. J., Ng, S.-Y., Gorz, M., Pilato, C. M., Ling, K., Kong, L., Ward, A. J., Rubin, L. L., et al. (2017) · Neuron · doi:10.1016/j.neuron.2016.11.033 · Cited by 136
“Splice-switching oligonucleotides (SSOs) and small molecules promote exon 7 inclusion in SMN2 pre-mRNAs and improve disease phenotypes in SMA mice (Hua et al., 2010; Hua et al., 2011; Naryshkin et al., 2014; Palacino et al., 2015).”
BackgroundSelf-citationRegulated control of gene therapies by drug-induced splicing
Mas, A., Hundley, A. A., Ranum, P. T., Tecedor, L., Muehlmatt, A., Lim, E., Lukashev, D. E., Sivasankaran, R., & Davidson, B. L. (2021) · Nature · doi:10.1038/s41586-021-03770-2 · Cited by 137
A large animal model of spinal muscular atrophy and correction of phenotype
Duque, S. I., Arnold, W. D., Odermatt, P., Li, X., Porensky, P. N., Schmelzer, L., Meyer, K., Kolb, S. J., Schümperli, D., Kaspar, B. K., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24332 · Cited by 135
Cheung, A. K., Hurley, B., Kerrigan, R., Shu, L., Chin, D. N., Shen, Y., O’Brien, G., Sung, M. J., Hou, Y., Axford, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01291 · Cited by 142
Self-citationNew treatments in spinal muscular atrophy: an overview of currently available data
Ramdas, S., & Servais, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1704732 · Cited by 142
“The second strategy employs small-molecule splicing modifiers that directly interact with the spliceosome to promote exon 7 inclusion [18] (Figure 2).”
BackgroundMechanistic studies of a small-molecule modulator of SMN2 splicing
Wang, J., Schultz, P. G., & Johnson, K. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800260115 · Cited by 136
Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA
Kong, L., Valdivia, D. O., Simon, C. M., Hassinan, C. W., Delestrée, N., Ramos, D. M., Park, J. H., Pilato, C. M., Xu, X., Crowder, M. E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb6871 · Cited by 140
Self-citationInhibition of RNA-binding proteins with small molecules
Wu, P. (2020) · Nature Reviews Chemistry · doi:10.1038/s41570-020-0201-4 · Cited by 146
Targeting RNA in mammalian systems with small molecules
Donlic, A., & Hargrove, A. E. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1477 · Cited by 130
“Concurrently, Metzger and co-workers from Roche reported a different class of molecules that demonstrated a dosedependent correction of SMN2 splicing to include exon 7 (Naryshkin et al., 2014).”
BackgroundRatni, H., Karp, G. M., Weetall, M. L., Naryshkin, N. A., Paushkin, S. V., Chen, K. S., McCarthy, K. D., Qi, H., Turpoff, A., Woll, M. G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00459 · Cited by 122
Self-citationIdentification of RNA structures and their roles in RNA functions
Cao, X., Zhang, Y., Ding, Y., & Wan, Y. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00748-6 · Cited by 150
Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy
Long, K. K., O’Shea, K. M., Khairallah, R. J., Howell, K., Paushkin, S., Chen, K. S., Cote, S. M., Webster, M. T., Stains, J. P., Treece, E., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy382 · Cited by 112
Self-citationNewborn screening for SMA in Southern Belgium
Boemer, F., Caberg, J., Dideberg, V., Dardenne, D., Bours, V., Hiligsmann, M., Dangouloff, T., & Servais, L. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.02.003 · Cited by 126
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
Sardone, V., Zhou, H., Muntoni, F., Ferlini, A., & Falzarano, M. S. (2017) · Molecules · doi:10.3390/molecules22040563 · Cited by 118
“These include the following: (i) ASO therapy for redirecting the splicing of exon 7 in SMN2 to increase the fulllength SMN2 transcript [26,27,28,29,30]; (ii) gene therapy of increasing functional SMN protein by introducing exogenous SMN1 gene using viral vectors [31,32,33,34]; and (iii) smallmolecule drugs to stimul…”
MethodSturm, S., Guenther, A., Jaber, B., Jordan, P., Kotbi, N. A., Parkar, N., Cleary, Y., Frances, N., Bergauer, T., Heinig, K., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13786 · Cited by 113
Self-citationAdvances in spinal muscular atrophy therapeutics
Parente, V., & Corti, S. P. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285618754501 · Cited by 106
Computer-aided design of RNA-targeted small molecules: A growing need in drug discovery
Manigrasso, J., Marcia, M., & Vivo, M. D. (2021) · Chem · doi:10.1016/j.chempr.2021.05.021 · Cited by 98
The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy
Singh, R. N., Ottesen, E. W., & Singh, N. N. (2020) · Neuroscience Insights · doi:10.1177/2633105520973985 · Cited by 100
Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain
Sumner, C. J., & Crawford, T. O. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121658 · Cited by 88
R-BIND: An Interactive Database for Exploring and Developing RNA-Targeted Chemical Probes
Morgan, B. S., Sanaba, B. G., Donlic, A., Karloff, D. B., Forte, J. E., Zhang, Y., & Hargrove, A. E. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00631 · Cited by 98
Taylor, J. L., Lee, F. K., Yazdanpanah, G., Staropoli, J. F., Liu, M., Carulli, J. P., Sun, C., Dobrowolski, S. F., Hannon, W. H., & Vogt, R. F. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.231019 · Cited by 91
“With multiple therapeutics currently in clinical trials, and more in development (1, 3, 19, 20), NBS laboratories are in an ideal position to facilitate presymptomatic intervention that could maximize the benefits of potential therapies.”
Barron, J. C., Hurley, E. P., & Parsons, M. P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.689332 · Cited by 85
Small molecule splicing modifiers with systemic HTT-lowering activity
Bhattacharyya, A., Trotta, C. R., Narasimhan, J., Wiedinger, K., Li, W., Effenberger, K. A., Woll, M. G., Jani, M., Risher, N., Yeh, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27157-z · Cited by 85
Self-citationPharmacology of Modulators of Alternative Splicing
Bates, D. O., Morris, J. C., Oltean, S., & Donaldson, L. F. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011239 · Cited by 90
“One approach has been to screen compounds for their ability to affect splicing using minigenes that express specific splice isoforms, then only selecting compounds that have specificity for that splice event (Naryshkin et al., 2014).”
BackgroundInfluentialIn Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide Metformin
Laustriat, D., Gide, J., Barrault, L., Chautard, É., Benoit‐Pilven, C., Auboeuf, D., Boland, A., Battail, C., Artiguenave, F., Deleuze, J., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.35 · Cited by 98
Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs
Velagapudi, S. P., Costales, M. G., Vummidi, B. R., Nakai, Y., Angelbello, A. J., Tran, T. A., Haniff, H. S., Matsumoto, Y., Wang, Z. F., Chatterjee, A. K., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.015 · Cited by 90
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Angelbello, A. J., Chen, J. L., Childs‐Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00504 · Cited by 81
RNA Splicing: A New Paradigm in Host–Pathogen Interactions
Chauhan, K., Kalam, H., Dutt, R., & Kumar, D. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.03.001 · Cited by 90
Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing
Chen, J. L., Zhang, P., Abe, M., Aikawa, H., Zhang, L., Frank, A. J., Zembryski, T., Hubbs, C., Park, H., Withka, J. M., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c00768 · Cited by 86
Use of artificial intelligence to enhance phenotypic drug discovery
Malandraki-Miller, S., & Riley, P. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.013 · Cited by 97
Identification of Small Molecule Inhibitors of Pre-mRNA Splicing
Pawellek, A., McElroy, S. P., Samatov, T. R., Mitchell, L., Woodland, A., Ryder, U., Gray, D. W., Lührmann, R., & Lamond, A. I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.590976 · Cited by 87
Amiloride as a new RNA-binding scaffold with activity against HIV-1 TAR
Patwardhan, N. N., Ganser, L. R., Kapral, G. J., Eubanks, C. S., Lee, J., Sathyamoorthy, B., Al‐Hashimi, H. M., & Hargrove, A. E. (2017) · MedChemComm · doi:10.1039/c6md00729e · Cited by 87
Catapano, F., Zaharieva, I. T., Scoto, M., Marrosu, E., Morgan, J. E., Muntoni, F., & Zhou, H. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.47 · Cited by 83
Li, Y., & Disney, M. D. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00827 · Cited by 76
Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy
Ahmad, S., Bhatia, K., Kannan, A., & Gangwani, L. (2016) · Journal of Experimental Neuroscience · doi:10.4137/jen.s33122 · Cited by 91
Zhou, H., Meng, J., Malerba, A., Catapano, F., Sintusek, P., Jarmin, S., Feng, L., Lu‐Nguyen, N., Sun, L., Mariot, V., et al. (2020) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12542 · Cited by 83
Liu, L., Chen, L., Zhang, Y., Wei, L., Cheng, S., Kong, X., Zheng, M., Huang, T., & Cai, Y. (2016) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2016.1138142 · Cited by 76
“Drugs target at the surveillance pathways of mRNA ( hsa03015 ) have been con fi rmed to interact with therapeutic speci fi c splicing modi fi ers (such as SMN2 splicing modi fi er), validating that mRNA surveillance pathways may interact with speci fi c DDIs (Naryshkin et al., 2014).”
BackgroundRegulatory mechanisms of incomplete huntingtin mRNA splicing
Neueder, A., Dumas, A. A., Benjamin, A. C., & Bates, G. P. (2018) · Nature Communications · doi:10.1038/s41467-018-06281-3 · Cited by 87
Recent advances in phenotypic drug discovery
Swinney, D. C., & Lee, J. A. (2020) · F1000Research · doi:10.12688/f1000research.25813.1 · Cited by 72
Small Molecules in Development for the Treatment of Spinal Muscular Atrophy
Calder, A. N., Androphy, E. J., & Hodgetts, K. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00670 · Cited by 81
Rational Design of Small Molecules Targeting Oncogenic Noncoding RNAs from Sequence
Disney, M. D., & Angelbello, A. J. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00326 · Cited by 76
Toward stem cell-based phenotypic screens for neurodegenerative diseases
Khurana, V., Tardiff, D. F., Chung, C. Y., & Lindquist, S. L. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.79 · Cited by 78
Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy
Sison, S. L., Patitucci, T. N., Seminary, E. R., Villalón, E., Lorson, C. L., & Ebert, A. D. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx230 · Cited by 78
Synthetic small-molecule RNA ligands: future prospects as therapeutic agents
Giorgio, A. D., & Duca, M. (2019) · MedChemComm · doi:10.1039/c9md00195f · Cited by 75
Jablonka, S., Hennlein, L., & Sendtner, M. (2022) · Neurological Research and Practice · doi:10.1186/s42466-021-00162-9 · Cited by 86
Therapeutic activity of modified U1 core spliceosomal particles
Rogalska, M. E., Tajnik, M., Licastro, D., Bussani, E., Camparini, L., Mattioli, C., & Pagani, F. (2016) · Nature Communications · doi:10.1038/ncomms11168 · Cited by 76
Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes
García-López, A., Tessaro, F., Jonker, H. R. A., Wacker, A., Richter, C. P., Comte, A., Berntenis, N., Schmucki, R., Hatje, K., Petermann, O., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04110-1 · Cited by 70
Self-citation
Metadata
- Authors
- Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., Chen, G., Zhang, N., Gabbeta, V., Vazirani, P., Bhattacharyya, A., Furia, B., Risher, N., Sheedy, J., Kong, R., Ma, J., Turpoff, A., Lee, C.-S., Zhang, X., Moon, Y.-C., Trifillis, P., Welch, E. M., Colacino, J. M., Babiak, J., Almstead, N. G., Peltz, S. W., Eng, L. A., Chen, K. S., Mull, J. L., Lynes, M. S., Rubin, L. L., Fontoura, P., Santarelli, L., Haehnke, D., McCarthy, K. D., Schmucki, R., Ebeling, M., Sivaramakrishnan, M., Ko, C.-P., Paushkin, S. V., Ratni, H., Gerlach, I., Ghosh, A., & Metzger, F.
- Affiliations
- PTC Therapeutics (United States) (US)
- University of Southern California (US)
- Spinal Muscular Atrophy Foundation (US)
- Harvard University (US)
- F. Hoffmann-La Roche AG (CH)
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, 4070 Basel, Switzerland.
- Corresponding author
- Peltz, Stuart W.
- Metzger, Friedrich
- ORCID
- Naryshkin, Nikolai A.
- Weetall, Marla
- Narasimhan, Jana
- Zhao, Xin
- Ling, Karen K. Y.
- Chen, Guangming
- Zhang, Nanjing
- Sheedy, Josephine
- Kong, Ronald
- Ma, Jiyuan
- Moon, Young-Choon
- Welch, Ellen M.
- Colacino, Joseph M.
- Peltz, Stuart W.
- Chen, Karen S.
- Rubin, Lee L.
- Fontoura, Paulo
- Ebeling, Martin
- Ko, Chien-Ping
- Paushkin, Sergey V.
- Ratni, Hasane
- Metzger, Friedrich
- Venue
- Science
- Published
- 2014-08-08
- Volume
- 345
- Issue
- 6197
- Pages
- 688-693
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1992985034
- Cited by
- 524
- References
- 56
- Citations by year
- 2026: 19 · 2025: 40 · 2024: 47 · 2023: 33 · 2022: 50 · 2021: 54 · 2020: 34 · 2019: 47 · 2018: 50 · 2017: 44 · 2016: 59 · 2015: 35 · 2014: 12
- FWCI
- 25.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- spinal muscular atrophy, SMN2, SMN1, alternative splicing, small molecules, SMN protein, motor function, lifespan extension, neuromuscular degeneration, compound screening
- MeSH terms
- Administration, Oral, Animals, Cells, Cultured, Coumarins, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Longevity, Muscular Atrophy, Spinal, Pyrimidinones, RNA, Messenger, Sequence Deletion, Alternative Splicing, Isocoumarins, Mice, Small Molecule Libraries, Survival of Motor Neuron 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.